You are asked to participate in this research study of a new immunotherapy combination with chemotherapy in metastatic triple negative breast cancer. Immunotherapy is a form of cancer therapy that activates a patient's immune system to fight the cancer in a patient's body. Unfortunately, only a limited number of patients with metastatic triple negative breast cancer currently respond to FDA approved forms of immunotherapy. CDX-301 and CDX-1140 are two new immunotherapy drugs that are thought to kickstart the immune response against cancers even in patients who do not have an adequate immune response against their cancer to start with. Some studies suggest that combining these drugs with chemotherapy can most effectively kickstart this immune response and lead to improved clinical outcomes.
You will have test, exams and procedures that are part of your standard care and for study purposes. While you are taking part in this study, you will be asked to attend between two and five visits per cycle with the researchers or study staff. This study involves blood draws, biopsies, physical exams, scans, pregnancy testing (if female), ECG and ECHO or MUGAs, completion of questionnaires and receipt of study medication. Patient who complete study treatment will move into long term follow up and will be contacted at regular intervals by the study team.
Hotel stay reimbursement will be provided up to $750 per cycle with your CDX-301 injections. Receipts will need to be provided to the study team for processing of this reimbursement.
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Yara Abdou
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Breast)
23-2746
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
